Ann Surg Oncol

1. BOYLE MK, Attiyeh MA, Amersi F, Chung A, et al
   Trends in Breast and Axillary Operations in Young Patients with Operable Breast Cancer from the National Cancer Database (NCDB): De-escalation of Axillary Surgery and Increased Use of Radiation.
   Ann Surg Oncol. 2026 Jul 2. doi: 10.1245/s10434-026-19993.
   

   >> Share

   
   
2. BOYLE MK, Attiyeh MA, Amersi F, Chung A, et al
   ASO Visual Abstract: Trends in Breast and Axillary Operations in Young Patients with Operable Breast Cancer from the National Cancer Database (NCDB)-De-escalation of Axillary Surgery and Increased Use of Radiation.
   Ann Surg Oncol. 2026 Jul 2. doi: 10.1245/s10434-026-20043.
   

   >> Share

   
   
3. GERVAIS C, Brouillette K, Benzouak T, Altuntur SK, et al
   ASO Visual Abstract: Impact of Surgical Delay on Breast Cancer Prognosis: Systematic Review and Meta-Analysis.
   Ann Surg Oncol. 2026 Jul 2. doi: 10.1245/s10434-026-20098.
   

   >> Share

   
   
4. VENKATESH H, Castro Gierach G, Kanzaki L, Ali A, et al
   Pregnancy-Associated Breast Cancer: A Trimester and Subtype Based Clinical Decision Framework for the Surgeon and Surgical Trainee.
   Ann Surg Oncol. 2026 Jul 1. doi: 10.1245/s10434-026-20101.
   

   >> Share

   
   
5. FENNIG S, Kirshtein A, Landman Y, Weiner N, et al
   Intraoperative Radiotherapy for Breast Cancer: Long-Term Experience.
   Ann Surg Oncol. 2026 Jun 29. doi: 10.1245/s10434-026-20078.
   

   >> Share

   
   
6. RADEMACHER N, Gutnik LA, Broman KK
   ASO Visual Abstract: Factors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node-Positive Breast Cancer who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy.
   Ann Surg Oncol. 2026 Jun 29. doi: 10.1245/s10434-026-20002.
   

   >> Share

   
   
7. LAUDE E, Guyon C, Diaz LM, Cabel L, et al
   ASO Visual Abstract: Association Between Axillary Surgical Management and Survival in Patients with de novo Metastatic Breast Cancer.
   Ann Surg Oncol. 2026 Jun 29. doi: 10.1245/s10434-026-20040.
   

   >> Share

   
   

   
   Anticancer Res

8. HAYASHI Y, Noma Y, Yoshinaga H, Takaoka R, et al
   Parathyroid Hormone-related Peptide Promotes Cancer-induced Bone Pain Through Direct Sensory Neuron Activation and Osteoclast-mediated Mechanisms.
   Anticancer Res. 2026;46:3721-3731.
   

   >> Share

   
   
9. WOO SH, Lee YH, Jung BC, Kim YS, et al
   Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells.
   Anticancer Res. 2026;46:3755-3769.
   

   >> Share

   
   

   
   BMC Cancer

10. BORG M, Farver-Vestergaard I, Hilberg O, Steed L, et al
    Long-term risk of depression in lung, colon, breast, and prostate cancer: a 25-year nationwide comparative study.
    BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16095.
    

    >> Share

    
    
11. QUISENAERTS T, Van Der Auwera I, Poortmans P, Reynders D, et al
    Preoperative Radiation Therapy and Immediate Breast Reconstruction, a phase 3 randomized controlled trial in the Belgian population (PRADAIIBE): a study protocol.
    BMC Cancer. 2026;26:743.
    

    >> Share

    
    
12. PARK R, Lee EY, Kang JW, Jun S, et al
    Effect of early exercise on functional recovery and surgical outcomes after post-mastectomy breast reconstruction: study protocol for a randomized clinical trial.
    BMC Cancer. 2026;26:731.
    

    >> Share

    
    
13. ALBALAWI ES, Qayyum J, Qayyum J
    Population-specific MicroRNA biomarker discovery in breast ductal carcinoma via explainable graph neural multi-omics modeling.
    BMC Cancer. 2026;26:721.
    

    >> Share

    
    
14. WANG Z, Cao Y, Wang Q, Wang L, et al
    Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study.
    BMC Cancer. 2026;26:651.
    

    >> Share

    
    
15. XIE Z, Wang K, Liu J, Hong Z, et al
    Stiripentol directly attenuates immunosuppression of tumor-infiltrating myeloid cells to potentiate anti-PD-1 efficacy.
    BMC Cancer. 2026;26:439.
    

    >> Share

    
    
16. LEE SF, Cokelek M, Yip PL, Bayley K, et al
    Dosimetric comparison of IMRT and VMAT with deep inspiration breath hold or free breathing for right-sided whole breast irradiation.
    BMC Cancer. 2026;26:429.
    

    >> Share

    
    
17. NAKAUCHI C, Masunaga N, Eguchi Y, Tanei T, et al
    Discordance between IHC/FISH and RNA expression-based assessment of ER/HER2 status, and its prognostic impact assessed by propensity score matching.
    BMC Cancer. 2026;26:808.
    

    >> Share

    
    
18. ALKEBBEH L, Berndt A, Oberkanins C, Kenj M, et al
    Comprehensive CYP2D6 genotyping improves phenotype classification and highlights methodological pitfalls in tamoxifen-treated breast cancer.
    BMC Cancer. 2026 Jul 1. doi: 10.1186/s12885-026-16440.
    

    >> Share

    
    
19. LAMY C, Laurent L, Choussy O, Pouget N, et al
    SCANDARE: an institutional dynamic prospective interventional biobanking study.
    BMC Cancer. 2026;26:330.
    

    >> Share

    
    
20. YANG Z, Dai Y, Li Y, Xia L, et al
    Routine biomarkers map response probability in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2 blockade.
    BMC Cancer. 2026 Jul 2. doi: 10.1186/s12885-026-16403.
    

    >> Share

    
    
21. LI X, Li C, Jiang L, Zheng D, et al
    Automated machine learning-based unenhanced radiomics for identification of HER2-low breast cancers using diffusion-weighted imaging.
    BMC Cancer. 2025;26:66.
    

    >> Share

    
    
22. KITONGO E, Segawa ES, Joyce N, Valeria N, et al
    Mammographic findings and BI-RADS concordance in women attending a community outreach program in Uganda.
    BMC Cancer. 2025;26:15.
    

    >> Share

    
    
23. HUANG D, Chen Y, Chen W, Wang Y, et al
    A predictive model for pathological complete response in neoadjuvant-treated breast cancer: integrating pretreatment clinicopathologic and contrast-enhanced ultrasound characteristics via interpretable machine learning.
    BMC Cancer. 2026 Jul 3. doi: 10.1186/s12885-026-16452.
    

    >> Share

    
    
24. XIANG C, Chen X, Mo F, Zhong Z, et al
    Plexin A2 regulated the metastasis in breast cancer through MCM7.
    BMC Cancer. 2026 Jul 3. doi: 10.1186/s12885-026-16355.
    

    >> Share

    
    

    
    Br J Cancer

25. ROMANOS-NANCLARES A, Bui LP, Rosner BA, Willett WC, et al
    Planetary Health Diet Index and breast cancer risk.
    Br J Cancer. 2026 Jun 30. doi: 10.1038/s41416-026-03523.
    

    >> Share

    
    

    
    Breast Cancer

26. RU L, Tang Y, Zhang J, Shi R, et al
    Time-dependent diffusion MRI for non-invasive differentiation of benign and malignant breast lesions and evaluation of proliferation index biomarkers.
    Breast Cancer. 2026;33:653-665.
    

    >> Share

    
    
27. KOKUBU Y, Osako T, Sakai T, Tomita Y, et al
    Causes of varied internal echo patterns in ultrasound imaging of breast lymphoma.
    Breast Cancer. 2026;33:582-592.
    

    >> Share

    
    
28. AOSHIKA T, Uchida N, Tomita F, Yamauchi R, et al
    Early outcomes of accelerated partial breast irradiation and dosimetric comparison of volumetric modulated arc therapy and three-dimensional conformal radiotherapy.
    Breast Cancer. 2026;33:675-682.
    

    >> Share

    
    

    
    Breast Cancer (Dove Med Press)

29. ABDEL-RAZEQ H
    Advancing Germline Genetic Testing for Breast Cancer in Resource-Restricted Settings: Evidence, Barriers, and a Practical Roadmap for Implementation.
    Breast Cancer (Dove Med Press). 2026;18:618067.
    

    >> Share

    
    
30. TAN Y, Zeng C, Zhao J, Zhao W, et al
    Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:574628.
    

    >> Share

    
    
31. MA X, Dang S, Wang H, Xia L, et al
    Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation.
    Breast Cancer (Dove Med Press). 2026;18:605051.
    

    >> Share

    
    

    
    Breast Cancer Res

32. DAHMS PA, Hinckley B, Prekeris R, Behbod F, et al
    Semaphorin-7A promotes macrophage-mediated mammary epithelial and ductal carcinoma in situ invasion.
    Breast Cancer Res. 2025;28:25.
    

    >> Share

    
    
33. ZHU Q, Bennett D, Hagemann IS, Mannix J, et al
    Ultrasound-guided diffuse optical tomography: an adjunct to ultrasound that can reduce unnecessary breast biopsies.
    Breast Cancer Res. 2025;28:31.
    

    >> Share

    
    
34. LIM GY, Ka NL, Kim SS, Lee MO, et al
    IFI16/IFI202 blockade suppresses tumor growth through CD8(+) T-cell-mediated immunity.
    Breast Cancer Res. 2026;28:27.
    

    >> Share

    
    
35. HE X, Tong W, Chen X, Huang H, et al
    TRPS1 confers paclitaxel resistance in TNBC through dual activation of the PDE4D-cAMP-AKT pathway and microtubule destabilization.
    Breast Cancer Res. 2026;28:47.
    

    >> Share

    
    
36. XU FF, Zheng SF, Shao ZY, Qi WX, et al
    The impact of immune microenvironment on local control of ductal carcinoma in situ receiving breast conservative therapy.
    Breast Cancer Res. 2026;28:50.
    

    >> Share

    
    
37. MAO X, Cao X, Qian L, Gao M, et al
    Vascular abnormalization confers tumor resistance to antiangiogenic therapy via downregulating angiostatic factors.
    Breast Cancer Res. 2026;28:59.
    

    >> Share

    
    
38. ELAHI SF, Martin DP, Wan Y, Zhang L, et al
    4-Hydroxybutyrate (4HB) released from poly-4-hydroxybutyrate scaffolds does not impact hallmark phenotypes of cancer in malignant or non-malignant breast cells.
    Breast Cancer Res. 2026;28:60.
    

    >> Share

    
    
39. ZHOU Y, Guo C, Wang Y, Xu H, et al
    Prognostic value of Ki-67 index in malignant phyllodes tumor of the breast: a multi-center real-world study.
    Breast Cancer Res. 2026;28:64.
    

    >> Share

    
    
40. WANG Z, Chen X, Han X, Cao X, et al
    Deubiquitination and stabilization of EIF4A3 by OTUB2 contributes to TPI1-mediated glycolysis and TNBC progression.
    Breast Cancer Res. 2026;28:77.
    

    >> Share

    
    
41. ALI S, Bains S, Fox E, Desai A, et al
    Prognostic significance of clinicopathological parameters, margin width and locoregional recurrences on outcome of primary and radiation associated breast angiosarcoma- results from a large UK sarcoma regional service.
    Breast Cancer Res. 2026;28:83.
    

    >> Share

    
    
42. SWITALLA KM, Onishi N, Jones EF, Lawhn-Heath C, et al
    A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy.
    Breast Cancer Res. 2026;28:93.
    

    >> Share

    
    
43. GAO T, Li K, Lei H, Wang J, et al
    Advantages of nitroglycerin application in preoperative CTA for DIEP flap breast reconstruction.
    Breast Cancer Res. 2026;28:95.
    

    >> Share

    
    
44. BI C, Li Q, Deng L, Ren Z, et al
    Prediction of pathologic upstaging in ductal carcinoma in situ using MRI radiomics combined with clinicopathological features.
    Breast Cancer Res. 2026;28:102.
    

    >> Share

    
    
45. LIGHTOWLERS SV, Roman-Escorza M, Welsh C, Bliss JM, et al
    Genomic and spatial analysis of local recurrences following risk-adapted breast radiotherapy in the IMPORT trials.
    Breast Cancer Res. 2026;28:108.
    

    >> Share

    
    
46. WANG X, Ni Y, Shi Y, Yu X, et al
    Exploring LTB-mediated T cell differentiation as a prognostic marker in triple-negative breast cancer.
    Breast Cancer Res. 2026 Jun 30. doi: 10.1186/s13058-026-02332.
    

    >> Share

    
    
47. FIORIN A, Adalid-Llansa L, Reverte L, Sauras-Colon E, et al
    Longitudinal evaluation of tumor-infiltrating lymphocyte scoring using automated region of interest registration in breast cancer.
    Breast Cancer Res. 2026 Jul 3. doi: 10.1186/s13058-026-02333.
    

    >> Share

    
    

    
    Breast J

48. KIM J, Lee Y, Yoon SY, Cho H, et al
    Factors Associated With Preoperative Radiological Tumor Size Underestimation in Clinical T1-2 Breast Cancer Patients.
    Breast J. 2026;2026:e3726326.
    

    >> Share

    
    
49. MANOHAR PM, Shankaran V, Davidson NE, Hunter N, et al
    Real-World Practice Patterns in Diagnosis and First-Line Treatment in Metastatic Breast Cancer.
    Breast J. 2026;2026:e4333748.
    

    >> Share

    
    
50. LUCARELLI AP, Martins MM, Teruya MM, Yauti TT, et al
    Systematic Review and Meta-Analysis: Association Between Circulating and Tissue Levels of Selenium and Zinc and Breast Cancer Risk.
    Breast J. 2026;2026:e7448703.
    

    >> Share

    
    

    
    Cancer Chemother Pharmacol

51. JOAO RB, Soares LR, Ragazzo PC, Freitas-Junior R, et al
    CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.
    Cancer Chemother Pharmacol. 2026;96:67.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

52. REGER MK, Maxey S
    Dietary phytoestrogen intake and risk of receptor-defined breast cancer subtypes: a prospective analysis of the PLCO Cancer Screening Trial cohort.
    Cancer Epidemiol Biomarkers Prev. 2026.
    

    >> Share

    
    
53. CANCHOLA AJ, Pruitt SL, Lin K, Boscoe FP, et al
    Ethnic Enclave Residence and Breast, Cervical, and Colorectal Cancer Incidence among Asian American Adults, 2006 to 2017.
    Cancer Epidemiol Biomarkers Prev. 2026;35:1139-1150.
    

    >> Share

    
    

    
    Cancer Lett

54. ZHANG H, Zhang L, He Y, Jiang D, et al
    Corrigendum to "PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer" [Cancer Lett. 598 (2024) 217112].
    Cancer Lett. 2026 Jun 30:218673. doi: 10.1016/j.canlet.2026.218673.
    

    >> Share

    
    

    
    Cancer Res

55. JURIC D, Islam KN, Gkotinakou IM, Zheng A, et al
    CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.
    Cancer Res. 2026 Jul 2. doi: 10.1158/0008-5472.CAN-25-1859.
    

    >> Share

    
    

    
    Clin Breast Cancer

56. YU D, Chen L, Li H, Kang S, et al
    LINC01234 Coordinates Protein Interactions and ceRNA Networks to Enhance YWHAZ-Driven Malignancy in Triple-Negative Breast Cancer.
    Clin Breast Cancer. 2026;26:64-74.
    

    >> Share

    
    

    
    Exp Cell Res

57. XIONG X, Wang Y, Liu C, Lu Q, et al
    Corrigendum to "Heat shock protein 90beta stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells" [Exp. Cell Res., 326, 1, 1 August 2014, Pages 78-89].
    Exp Cell Res. 2026 Jun 28:115106. doi: 10.1016/j.yexcr.2026.115106.
    

    >> Share

    
    

    
    Int J Cancer

58. LI L, Zarean E, Li DL, Zhu Y, et al
    Epigenetic Markers of Cell Division and Ageing in Relation to Breast Cancer Survival.
    Int J Cancer. 2026 Jun 27. doi: 10.1002/ijc.70618.
    

    >> Share

    
    

    
    J Natl Cancer Inst

59. CREW KD, Anderson GL, Arnold KB, Dzingle S, et al
    Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.
    J Natl Cancer Inst. 2026 Jul 2:djag216. doi: 10.1093.
    

    >> Share

    
    

    
    Lancet Oncol

60. YAO H, Zhang Q, Li H, Yin Y, et al
    Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2026 Jul 1:S1470-2045(26)00193.
    

    >> Share

    
    
61. FAN Y, Zhang H, Tang S, Toi M, et al
    Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases.
    Lancet Oncol. 2026;27:e325-e338.
    

    >> Share

    
    
62. SHAMAI G, Kimmel R, Aran D
    The intermediate-risk gap in AI-based breast cancer stratification - Authors' reply.
    Lancet Oncol. 2026;27:e318.
    

    >> Share

    
    
63. KOINIS F, Saloustros E, Kotsakis A
    The intermediate-risk gap in AI-based breast cancer stratification.
    Lancet Oncol. 2026;27:e317.
    

    >> Share

    
    
64. KAIDAR-PERSON O, Weltens CG, Fortpied C, Scheijmans LJEE, et al
    Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.
    Lancet Oncol. 2026;27:817-829.
    

    >> Share

    
    
65. MAURITZ AJW, de Munck L, Simons JM, Verloop J, et al
    Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study.
    Lancet Oncol. 2026;27:808-816.
    

    >> Share

    
    
66. SEEFAT RL, Vliek SB, de Jong VMT, Balduzzi S, et al
    Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2026;27:795-807.
    

    >> Share

    
    
67. MITCHELL M
    Customised radiation after neoadjuvant chemotherapy in breast cancer.
    Lancet Oncol. 2026;27:764-765.
    

    >> Share

    
    

    
    NPJ Breast Cancer

68. WANG W, Zhang C, Muluneh B, Li Q, et al
    Patient-reported outcomes as early indicators of recurrence, disease progression, and survival via machine learning in breast cancer.
    NPJ Breast Cancer. 2026 Jun 27. doi: 10.1038/s41523-026-01001.
    

    >> Share

    
    
69. YANG R, Xu YL, Wang Y, Xing WY, et al
    Flavonoid-rich foods, genetic risk, and female breast cancer risk: a prospective cohort study.
    NPJ Breast Cancer. 2026 Jun 30. doi: 10.1038/s41523-026-00989.
    

    >> Share

    
    
70. RASIC D, Pouplier SS, Jensen MB, Ejlertsen B, et al
    AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naive luminal breast cancer.
    NPJ Breast Cancer. 2026 Jul 1. doi: 10.1038/s41523-026-00999.
    

    >> Share

    
    
71. ZHANG S, Queen KJ, Duggirala N, Yang E, et al
    Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX(R) test in women with HR+, HER2-negative breast cancer.
    NPJ Breast Cancer. 2026 Jul 1. doi: 10.1038/s41523-026-01002.
    

    >> Share

    
    
72. SYMMANS WSO, Tran K, Fu C, Sun H, et al
    Stage-related transcriptional changes in HR-positive/HER2-negative breast cancer.
    NPJ Breast Cancer. 2026 Jul 2. doi: 10.1038/s41523-026-00973.
    

    >> Share

    
    

    
    Oncogene

73. YANG X, Su Y, Ying Y, Peng Y, et al
    DNA methylation-mediated silencing of STAT5A drives breast cancer metastasis via dual regulation of EMT and immunosuppressive microenvironment.
    Oncogene. 2026 Jun 29. doi: 10.1038/s41388-026-03849.
    

    >> Share

    
    

    
    PLoS One

74. CHENG Y, Jiang YN, Zhang Q
    Navigating ethical waters: The impact of ethical judgment, norms, and CSR skepticism on CSR engagement and purchasing intention in a breast cancer campaign.
    PLoS One. 2026;21:e0352994.
    

    >> Share

    
    
75. 
    Editorial Note: Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer.
    PLoS One. 2026;21:e0352941.
    

    >> Share

    
    
76. MOHTAR MA, Fessart D, Yuh Cai C, Zahari S, et al
    Genetic regulatory axis between AGR2 and ESR1 promotes breast cancer progression.
    PLoS One. 2026;21:e0351873.
    

    >> Share

    
    
77. ISHII H, Nishiyama K, Nakahara A, Tamori S, et al
    Cell-cell junction gene signatures as subtype-specific prognostic biomarkers in breast cancer.
    PLoS One. 2026;21:e0352254.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share